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We studied the presence of donor-specific T lymphocytes in explanted 
human cardiac valve allografts in vivo. From five of seven explants we 
propagated lymphocyte cultures in an interleukin-2 conditioned medium. 
Phenotyping revealed the presence of T-cell receptors in more than 95% of 
the lymphocytes obtained in each culture. Donor-specific ytotoxicity was 
demonstrated in three patients with known HLA status of the donor. 
Cytotoxicity was directed against only HLA class I in one patient, and 
against class I and/or class II in the others. These results indicate that 
donor-specific cellular reactivity can be induced by transplantation of 
human cardiac valve allografts. (J Thorac Cardiovasc Surg 1996;112:281-6) 
H uman cardiac valve allografts are transplanted without the immunosuppressive therapy nor- 
mally given to recipients of vascularized organ trans- 
plants because it is supposed that antigenicity does 
not play a major role. However, early valve failure is 
not uncommon and, especially in children, other 
causes besides technical ones are suggested to play a 
role. 1 In animal models the antigenicity of valve 
allografts was illustrated earlier. 2' 3 Sensitization of 
the recipient against allogeneic valves was revealed 
by the rejection of donor-specific skin transplants 4 
and by the measurement of  allogeneic antibodies. 5 
Recently, a donor-specific cellular immune response 
in vivo has been demonstrated in rat spleen cells 
after valve allograft transplantation. 6 Studies on the 
antigenicity of human valve allografts have been 
limited to sparse descriptions of histologic findings 
of  infiltrates in explanted valves]  In addition, we 
showed stimulation of immune competent cells by 
human valve leaflets in vitro? 
In the present study, we examined the in vivo 
immune response after transplantation of human 
cardiac valves. We cultured graft-infiltrating lym- 
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phocytes from explanted human cardiac donor 
valves and tested them for donor-specific reactivity. 
Patients and methods 
Patients. Valve recipients were between 8 months and 
60 years of age at the time of transplantation. Valve 
allografts (four aortic and three pulmonary) were ob- 
tained from heart-beating (n = 6) and non-heart-beating 
(n = 1, patient 1) donors after preparation and cryo- 
preservation according to the Standard Preparation Pro- 
tocol of the Heart Valve Bank Rotterdam? Three valves 
were placed in the aortic position and four were used to 
reconstruct the right ventricular outflow tract. The inter- 
val between transplantation and explantation, the causes 
of vane failure leading to explantation, and the HLA type 
of the vane donor are shown in Table I. Four valves were 
explanted between 19 and 84 months after transplantation 
because of structural vane failure, which refers to changes 
intrinsic to the vane, causing stenosis or regurgitation. 1° 
One vane was explanted because of nonstructural vane 
deterioration 6 months after transplantation. Nonstruc- 
tural dysfunction refers to any abnormality resulting in 
stenosis or regurgitation that is not caused by intrinsic 
changes of the vane. Two allografts were explanted for 
non-valve-related reasons (in one case the allograft was 
obtained at autopsy after the recipient had died in a car 
accident, and in the other case it was obtained 4.5 hours 
after transplantation for technical reasons because of 
takedown of intracardiac repair). HLA typing of the vane 
donor was performed on spleen cells or peripheral blood 
mononuclear cells, isolated on Ficoll-paque (d = 1.077) 
density gradient centrifugation (Pharmacia, Uppsala, 
Sweden) separation. HLA class I antigens were typed 
according to the standard National Institutes of Health 
lymphocytotoxicity assay. Highly selected antisera were 
used for HLA-DR typing. 11 The HLA type of the valve 
recipients was not available. The Medical Ethical Com- 
mittee of the University Hospital Rotterdam approved the 
studies. 
Culture method. From each explanted valve, the valve 
leaflets were cut into 2 mm diameter pieces with a biopsy 
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Table I. Patient characteristics 
Age at time of Graft 
Pat ient  transplantation HLA-type donor survival Mode of faihtre 
1 25 yr Unknown 84 mo 
2 8 mo AI,2 B7,8 DR2,3 46 mo 
3 35 yr A2,32 B51 DRl1,13 6 mo 
4 8 yr A2 B62 DR2,4 30 mo 
5 60 yr A2,30 B51,62 DR4 5 mo 
6 20 yr A2 B7,60 DR2,4 19 mo 
7 4 yr A1,32 B51,8 DR17,12 4.5 hr 
Structural deterioration 
Structural deterioration 
Nonstructural deterioration 
Structural deterioration 
Nonvalve-related patient death 
Structural deterioration 
Not valve related 
Table I I .  Lymphocyte culture characteristics 
Cell growth Phenotype cultures Donor-specific lysis 
Patient Leaflet Vessel Leaflet Vessel Leaflet Vessel 
1 + ND 52% WT31/CD4 
46% WT31/CD8 
2 ND + 
3 + + 58% WT31/CD4 
40% WT31/CD8 
4 + + 95% WT31/CD4 
5 + ND 16% WT31/CD4 
83% WT31/CD8 
6 - ND 
7 - ND 
97% WT31/CD4 
58% WT31/CD4 
39% WT31/CD8 
57% WT31/CD4 
27% WT31/CD8 
15% TCR gamma/delta 
ND ND 
+ + 
- + 
+ 
ND, Not done; TCR, T-cell receptor. 
punch (Stiefel Laboratories Ltd., Woodwin Green Bucks, 
United Kingdom). These pieces were placed in 96-well 
round-bottomed tissue culture plates (Costa r 3799, Cor- 
ning Costar Corp., Cambridge, Mass.) with 200/xl culture 
medium, which consisted of RPMI 1640 Dutch Modifica- 
tion (Gibco Laboratories, Paisley, Scotland) supple- 
mented with 10% heat-inactivated human serum, 10% 
vol/vol lectin-free Lymphocult-T-LF medium (Biotest 
Pharma GmbH, Dreieich, Germany), an exogenous 
source Qf interleukin-2, L-glutamine 4 retool/L, penicillin 
100 IU/ml, and streptomycin 100 ~g/ml. Irradiated (40 
Gy) autologous or third-party peripheral blood mononu- 
clear cells (1.105 cells per well) served as feeder. Periph- 
eral blood mononuclear cells were isolated on Ficoll- 
paque. The cultures were grown at 370 C in a humidified 
atmosphere with 5% carbon dioxide, and every 2 to 3 days 
half the medium was replaced by fresh culture medium. 
When growth of lymphocytes was observed, the pieces 
were removed and the contents of several wells were 
pooled. When sufficient cell density was reached, the 
contents of the wells were transferred to more wells. 
Pllenotypie analysis. T-cell lines were analyzed by 
three-color flow cytometry for the expression of cell 
surface antigens after staining with monoclonal antibod- 
ies. A pan T-cell marker, WT31, recognizing T-cell recep- 
tor alpha/beta, was used, and anti-Leu-3 (CD4) and 
anti-Leu-2 (CD8) were used as T-cell subset markers. 
Anti-Leu-19 (CD56) and anti-Leu-11 (CD16) were used 
as markers for natural killer cells, and l l F2  was used as 
marker for T-cell receptor gamma/delta expression. Anti- 
bodies were directly conjugated to fluorescein isothiocya- 
hate, phycoerythrin, or peridenin chlorophyll protein 
(Becton Dickinson & Co., Mountain View, Calif.). A total 
of 5.104 cells were incubated with fluoresceinated mono- 
clonal antibodies for 30 minutes at room temperature. 
Cells were subsequently Washed in phosphate-buffered 
saline solution and 5000 cells were analyzed in a lympho- 
cyte gate on an FACScan (Becton Dickinson). Lympho- 
cyte gate was set on forward and sideward light scatter, 
and cell debris was gated out by a threshold on forward 
light scatter. 
Cell-mediated cytotoxicity. A standard 4-hour chro- 
mium 51 release assay 12 was performed to measure the 
cytotoxic apacity of the cultures against a panel of target 
cells, sharing one or more HLA antigens with the valve 
donor. Three types of target cells were used: phytohem- 
agglutinin-blasts as target for activity against HLA class I
antigens, Epstein-Barr virus transformed B-cell lines as 
targets for class I and class II antigens, and the K562 and 
Daudi cell lines as control for natural killer cell and 
lymphokine-activated killer cell activity. 
A total of 3.103 SlCr:labeled target cells per well were 
placed in 96-well r0und-bottomed culture plates, and 
effector cells were added at an effector target ratio from 
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Fig. 1. Donor-specific lympholysis by valve allografl infiltrating cells. Patient 3: lymphocyte cultures 
derived from the vessel wall. HLA antigens that are matched with valve donor antigens are underlined in 
the key, LAK, lymphokine-activated killer cell. 
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Fig. 2. Donor-specific lympholysis by valve allograft infiltrating cells. Patient 3: lymphocyte cultures 
derived from the valve leaflet. HLA antigens that are matched with valve donor antigens are underlined in 
the key. LA/~ lymphokine-activated killer cell. 
_~_ = A1 A2. B8 B5__! DR4 DR11 
= A2 A28 B44 860 DR13 DR14 
-~- = A24 A3___22 B51 818 DR12 DR13 
-4- = Daudi~ LAK activity 
= negative control: A] A23 B17 B37 DR7 
2 8 4 Hoekstra et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1996 
W 
W 
o~ 
1 O0 
80 
60 
40 
20 
1.25:1 
\ 
I I 
2.5:1 5:1 10:1 20:1 
-~- = A_~2 A3 B6__~2 B18 
--~ = A1 A2 B51 B8 DR4 DR11 
--~ = A3 B35 DR1 DR15 
~-  = Daudi, LAK activity 
= negative control: A3 A23 B44 DR12 DR7 
E:T ratio 
Fig. 3. Donor-specific lympholysis by valve allograft infiltrating cells. Patient 4: lymphocyte cultures 
derived from the vessel wall. HLA antigens that are matched with valve donor antigens are underlined in 
the key. LAK, lymphokine-activated killer cell. 
1:1 to 20:1. The plates were centrifuged (60 g, 1 minute) 
and incubated for 4 hours at 37°C in a humidified 
atmosphere with 5% carbon dioxide. Supernatants were 
collected with a Skatron harvesting system (Skatron A/S, 
Lierse, Norway) and counted in a gamma counter for 3 
minutes. Percentage lysis was calculated according to the 
formula: 
Percent lysis 
Experimental release - Spontaneous release 
= × 100 
Maximal release - Spontaneous release 
Maximal release was determined in fourfold from an 
octyphenoxy polyethoxyethanol lysate* of the target cells. 
Spontaneous release was determined in fourfold by incu- 
bation of target cells in medium (RPMI 1640 Dutch 
Modification, supplemented with 1% heat-inactivated se-
rum). Cultures were considered cytolytic when the exper- 
imental lysis percentage xceeded 10% at an effector/ 
target ratio of 20:1 or greater and the slope of the graph 
was positive. 12 
Numeric results are presented as median with range. 
Clinical and allograft characteristics were compared with 
the Wilcoxon test or Student's t test where appropriate. A 
p value smaller than 0.05 was considered to be significant. 
*Triton X 100 (Union Carbide Corp., Danbury, Conn.), 5% 
vol/vol solution in tromethamine buffer, 0.01 mol/L. 
Results 
Although several explants showed macroscopic 
and microscopic signs of calcification, lymphocyte 
cultures were obtained from five of seven available 
human cardiac donor valves from the valve leaflet or 
the vessel wall (Table II). These cultures all con- 
tained 95% or more T-cell receptor-bearing cells. 
The median percentage of CD8 positive lympho- 
cytes in these cultures was 40% (range 27% to 83%), 
and the median percentage of CD4 positive lympho- 
cytes was 58% (range 16% to 97%) (Table II). One 
lymphocyte culture was obtained from a valve of 
which the HLA status of the donor was not available 
and could not be tested for donor specificity in a 
cell-mediated lympholysis assay. One allograft had 
been transplanted for only 4.5 hours and served as a 
control for the test system. This valve explant indeed 
did not generate a lymphocyte culture. Finally, six 
cultures derived from four remaining explants were 
tested in a cell-mediated lympholysis assay against a 
panel of target cells sharing one or more HLA 
antigens with the valve donor. More than 60% lysis 
of cells sharing HLA antigens with the valve donor 
was observed in four cultures, derived from three 
explants (patients 3, 4, and 5, Figs. 1 to 4). No 
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Fig. 4. Donor-specific lympholysis by valve allograft infiltrating cells. Patient 5: lymphocyte cultures 
derived from the valve leaflet. HLA antigens that are matched with valve donor antigens are underlined in 
the key. LAK, lymphokine-activated killer cell. 
correlation was found between explants showing 
donor-specific lysis, age at the time of implantation, 
graft survival, or mode of failure. In patient 2 the 
culture consisted of CD4 positive cells only and 
showed no cytotoxic reactivity. As shown in Table II, 
in two cases lymphocyte cultures were generated 
from both valve leaflet and vessel wall (patients 3 
and 4). The phenotype of the two cultures derived 
from the allograft and vessel wall in patient 3 were 
identical, whereas the phenotype of these two cul- 
tures differed in patient 4. 
As negative controls, third-party cells (sharing no 
HLA antigens with the donor) were used in the 
cytotoxicity test. These cells were not lysed, and in 
addition both natural killer cell and lymphokine- 
activated killer cell activity remained within rela- 
tively low ranges (Figs. 1 to 4). According to these 
results, cytotoxicity of the recipient lymphocytes was 
documented against class I antigens of the donor in 
one patient (patient 4), whereas in the other two 
patients cytotoxicity might be directed against class I
or class II antigens, or both. 
Discussion 
From earlier in vitro and experimental animal 
studies it was clear that cardiac valve allografts are 
able to stimulate the immune system. 2-6 In the 
present study, we showed for the first time in a 
functional way that after valve allograft ransplanta- 
tion, cytotoxic lymphocytes are generated in at least 
some allografts (five of six in our study) that are 
specifically directed against donor antigens. We 
cultured alloreactive T cells in interleukin-2 condi- 
tioned medium, in which only activated interleu- 
kin-2 receptor bearing lymphocytes are supposed to 
grow. Similar immunologic methods have already 
been applied to characterize graft-infiltrating cells 
after solid organ transplantation. 13-15 In these re- 
ports a correlation between the presence of donor- 
specific cytotoxic T cells in the graft and rejection 
was described, confirming the clinical relevance of 
these studies. The small number of our present- 
series cardiac valve allografts prohibits us from 
making a correlation between in vivo data and 
patient characteristics. Nevertheless, our study un- 
equivocally demonstrates lymphocytes infiltrating 
the transplanted valve, which may lead to immuno- 
logic inflammation, potentially resulting in tissue 
damage and thus allograft dysfunction. Endothelial 
cells probably play a key role in this process. Previ- 
ously we showed that valve endothelial cells are able 
to induce lymphoproliferation, and heart endothe- 
lial cells can also be targets for cytotoxic lympho- 
cytes.16, 17 We also detected antibodies against do- 
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nor HLA in 14 of 21 (67%) living patients with the 
allograft valve in place. Although valve allograft 
dysfunction does not necessarily result in cardiac 
failure, a significant number of valve replacements is 
necessary, especially in young recipients. 1 
In conclusion, our study shows that donor-di- 
rected immune mechanisms are among the factors 
possibly leading to tissue damage and valve allograft 
failure. Prospective immunologic monitoring is 
needed to assess the relative importance of this 
particular factor. Manipulation of the allograft to 
reduce the antigenicity should be considered, and 
indeed, cryopreservation is associated with a lower 
immunogenicity han fresh valve allografts. 8 In the 
present study we found activity against class I and 
class II antigens, and we already showed in vitro 
evidence for the importance of class II matching, 8 
which could be considered in individual patients in 
case of second valve replacements and in children 
with their high risk of valve failure. Alternatively, 
low-dose immunosuppression could be given to pa- 
tients in whom the risk of valve failure is high, 1 but 
only for a short while, because complications of 
long-term immunosuppression may not outweigh its 
benefits. 
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